Metropolitan Life Insurance Company (MetLife)’s Epizyme, Inc EPZM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-26,763
| Closed | -$66.9K | – | 2786 |
|
|
2021
Q4 | $66.9K | Buy |
26,763
+4,410
| +20% | +$17.3K | ﹤0.01% | 2657 |
|
|
2021
Q3 | $114K | Sell |
22,353
-18,087
| -45% | -$110K | ﹤0.01% | 2450 |
|
|
2021
Q2 | $336K | Buy |
40,440
+16,656
| +70% | +$140K | ﹤0.01% | 2261 |
|
|
2021
Q1 | $207K | Buy |
23,784
+841
| +4% | +$8.7K | ﹤0.01% | 1999 |
|
|
2020
Q4 | $249K | Sell |
22,943
-4,658
| -17% | -$57.5K | ﹤0.01% | 1793 |
|
|
2020
Q3 | $329K | Hold |
27,601
| – | – | 0.01% | 1484 |
|
|
2020
Q2 | $443K | Buy |
27,601
+4,252
| +18% | +$74.2K | 0.01% | 1300 |
|
|
2020
Q1 | $362K | Sell |
23,349
-2,128
| -8% | -$45.7K | 0.01% | 1240 |
|
|
2019
Q4 | $627K | Sell |
25,477
-729
| -3% | -$10.8K | 0.01% | 1186 |
|
|
2019
Q3 | $270K | Buy |
26,206
+4,799
| +22% | +$60.5K | ﹤0.01% | 1668 |
|
|
2019
Q2 | $269K | Buy |
21,407
+1,837
| +9% | +$23.6K | ﹤0.01% | 1690 |
|
|
2019
Q1 | $242K | Buy |
19,570
+3,029
| +18% | +$33.9K | ﹤0.01% | 1775 |
|
|
2018
Q4 | $102K | Hold |
16,541
| – | – | ﹤0.01% | 2255 |
|
|
2018
Q3 | $175K | Hold |
16,541
| – | – | ﹤0.01% | 2087 |
|
|
2018
Q2 | $224K | Buy |
16,541
+670
| +4% | +$10.4K | ﹤0.01% | 1873 |
|
|
2018
Q1 | $282K | Hold |
15,871
| – | – | ﹤0.01% | 1661 |
|
|
2017
Q4 | $199K | Sell |
15,871
-14,809
| -48% | -$215K | ﹤0.01% | 1913 |
|
|
2017
Q3 | $584K | Hold |
30,680
| – | – | ﹤0.01% | 1580 |
|
|
2017
Q2 | $463K | Hold |
30,680
| – | – | ﹤0.01% | 1747 |
|
|
2017
Q1 | $526K | Hold |
30,680
| – | – | ﹤0.01% | 1615 |
|
|
2016
Q4 | $371K | Buy |
30,680
+3,269
| +12% | +$34.1K | ﹤0.01% | 1931 |
|
|
2016
Q3 | $270K | Sell |
27,411
-3,674
| -12% | -$33.5K | ﹤0.01% | 2140 |
|
|
2016
Q2 | $318K | Hold |
31,085
| – | – | ﹤0.01% | 1993 |
|
|
2016
Q1 | $377K | Buy |
31,085
+10,491
| +51% | +$106K | ﹤0.01% | 1765 |
|
|
2015
Q4 | $330K | Hold |
20,594
| – | – | ﹤0.01% | 1902 |
|
|
2015
Q3 | $265K | Sell |
20,594
-647
| -3% | -$13.1K | ﹤0.01% | 2081 |
|
|
2015
Q2 | $510K | Buy |
21,241
+10,959
| +107% | +$211K | ﹤0.01% | 1731 |
|
|
2015
Q1 | $193K | Hold |
10,282
| – | – | ﹤0.01% | 2077 |
|
|
2014
Q4 | $194K | Hold |
10,282
| – | – | ﹤0.01% | 2438 |
|
|
2014
Q3 | $279K | Hold |
10,282
| – | – | ﹤0.01% | 2136 |
|
|
2014
Q2 | $320K | Buy |
+10,282
| New | +$242K | ﹤0.01% | 2150 |
|
|
2013
Q4 | – | Sell |
-4,154
| Closed | -$167K | – | 2765 |
|
|
2013
Q3 | $167K | Sell |
4,154
-3,427
| -45% | -$116K | ﹤0.01% | 2550 |
|
|
2013
Q2 | $213K | Buy |
+7,581
| New | +$195K | ﹤0.01% | 2311 |
|
Other funds holding EPZM
RM
RSCM
PAI
PIM
Metropolitan Life Insurance Company (MetLife)'s EPZM Position: Q1 2022 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Epizyme, Inc (EPZM) in Q1 2022, closing a stake of 26,763 shares — an estimated $66.9K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in EPZM in Q2 2013 and held it in 33 quarters. The position peaked at $627K in Q4 2019. 120 funds tracked by Wall St. Rank hold EPZM as of Q1 2022.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Epizyme, Inc position as of Q1 2022 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 26,763 Epizyme, Inc shares in Q1 2022, an estimated $66.9K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Epizyme, Inc in Q2 2013 and held it in 33 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Epizyme, Inc position peaked at $627K in Q4 2019.
- 120 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2022.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.